Santen acquisition of Eyevance : Santen Pharmaceutical, a Japanese pharma company specialized in ophthalmology, has acquired US ophthalmic company Eyevance Pharmaceuticals for $225 million in cash. The acquisition was undertaken by the company’s fully-owned subsidiary Santen Holdings U.S. Established only a couple of years ago, Eyevance Pharmaceuticals develops and commercializes topical ophthalmic products that target the […]
Eyevance Pharmaceuticals has made a significant move in the ophthalmic drug market by acquiring the global licensing rights for Nexagon, an advanced antisense oligomer drug, from OcuNexus Therapeutics. This strategic acquisition positions Eyevance at the forefront of developing new treatments for persistent corneal epithelial defect (PED), a challenging condition resistant to conventional therapies. Eyevance Pharmaceuticals […]